Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, as determined by a responsible and experienced physician~* Male or female between 18 and 45 years of age~* Body weight \>50 kg (110 lbs) for males or \>45 kg (100 lbs) for females, and body mass index (BMI) between 19.0 and 24.0 kg/m2~Exclusion Criteria:~* Positive result for hepatitis B, hepatitis C or HIV at screening~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities~* Positive urine drug screen and breath alcohol test at screening or prior to dosing~* Lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- TDF tablets (Type: EXPERIMENTAL): Tenofovir disoproxil fumarate tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).